Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Navigating the Complexity of Dual Clonality in Cutaneous Lymphoma: Challenge.

The American Journal of dermatopathology·2026
Same author

Erratum: Cutaneous Involvement by Diffuse Large B-Cell Lymphoma With Dual B-Cell and T-Cell Clonality and Heavy Admixed T-Cell Infiltrate: Answer.

The American Journal of dermatopathology·2026
Same author

Dermatomal Zosteriform Eruption After Sequential Intralesional Bleomycin and Excision.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026
Same author

Decoding cellular communication networks and signaling pathways in bone, skeletal muscle, and bone-muscle crosstalk through spatial transcriptomics in a young male mouse.

Bone research·2026
Same author

CDCP1 Deletion Protects Against Pressure Overload-Induced Cardiac Dysfunction and Fibrosis in Mice.

Research square·2026
Same author

Evaluation of Senior General Surgery Residents in the Teaching Assistant Role for Inguinal Hernia Repair.

Journal of surgical education·2026

Related Experiment Video

Updated: Jun 21, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.

Anne Han1, Elbert H Chen, George Niedt

  • 1Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA. dr.annehan@gmail.com

Archives of Dermatology
|July 22, 2009
PubMed
Summary
This summary is machine-generated.

Neoadjuvant imatinib therapy before Mohs surgery effectively reduced tumor size and improved histopathology in patients with dermatofibrosarcoma protuberans (DFSP), achieving 100% local control. This approach offers a well-tolerated option for managing this rare soft-tissue tumor.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 21, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

  • Oncology
  • Dermatology
  • Surgical Pathology

Background:

  • Dermatofibrosarcoma protuberans (DFSP) is a rare soft-tissue neoplasm known for its infiltrative growth and high recurrence rates after surgical excision.
  • Standard surgical treatments for DFSP can lead to significant functional and cosmetic deficits due to the tumor's subclinical extension.

Purpose of the Study:

  • To evaluate the efficacy and safety of neoadjuvant imatinib mesylate therapy in patients with locally advanced or recurrent DFSP prior to Mohs micrographic surgery.
  • To assess the impact of neoadjuvant imatinib on tumor burden, histopathological characteristics, and local recurrence rates.

Main Methods:

  • Retrospective analysis of data from 4 patients with locally advanced or recurrent DFSP.
  • Patients received neoadjuvant imatinib mesylate therapy before undergoing Mohs micrographic surgery.
  • Tumor response was assessed through clinical size reduction and histopathological examination.

Main Results:

  • Neoadjuvant imatinib therapy resulted in an average tumor size reduction of 36.9%.
  • Histopathological analysis revealed decreased cellularity and significant hyalinization in all treated tumors.
  • The treatment regimen was associated with 100% local tumor control at a maximum follow-up of 4 years.

Conclusions:

  • Neoadjuvant imatinib mesylate is a well-tolerated and effective therapeutic strategy for DFSP, reducing tumor volume and facilitating surgical resection.
  • This approach represents a novel option for managing DFSP, particularly in cases of locally advanced or recurrent disease.
  • Further investigation through larger prospective studies is warranted to validate these findings and establish optimal treatment protocols.